Wyndham Hotels & Resorts

WH · NYSE

$77.35+$1.16 (+1.52%)TodayMarket closed · Oct 20, 7:31 PM ET

Prev close $76.19

WH analyst rating

BuyConsensus of 11 analysts over the last 12 months. 73% rate it a buy.

Strong buy0
Buy8
Hold3
Underperform0
Sell0

12-month price target · 20 analysts

Average $99.83 (+29.1% upside)

Low: $80.80
Now: $77.35
High: $120.75

Upgrades and downgrades

The latest rating actions, newest first

WH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Freedom Broker	Oct 14, 2026	Initiates	Buy	$88.00	67%
Morgan Stanley	Oct 12, 2026	Maintains	Overweight	$91.00 → $92.00	58%
Truist Securities	Sep 10, 2026	Maintains	Buy	$107.00 → $104.00	53%
Morgan Stanley	Aug 18, 2026	Maintains	Overweight	$93.00 → $91.00	58%
Susquehanna	Aug 11, 2026	Maintains	Neutral	$90.00 → $80.00	66%
JP Morgan	Jul 21, 2026	Maintains	Overweight	$100.00 → $97.00	48%
Barclays	Jul 21, 2026	Maintains	Overweight	$104.00 → $102.00	46%
Morgan Stanley	Jul 17, 2026	Maintains	Overweight	$89.00 → $93.00	58%
Wells Fargo	Jul 16, 2026	Maintains	Equal-Weight	$96.00 → $98.00	33%
Morgan Stanley	May 12, 2026	Maintains	Overweight	$87.00 → $89.00	58%

The case for and against

Updated Oct 22, 2025

Bull case

Wyndham Hotels & Resorts has demonstrated a robust operational performance, achieving an 11% growth in earnings per share (EPS) despite a challenging environment that included a 3% decline in revenue per available room (RevPAR). The company has also successfully expanded its room count by 350 basis points year-over-year, notably enhancing its presence in both the domestic and international markets, with strong growth of 6% in EMEA and 25% in Latin America for RevPAR. Furthermore, Wyndham's strategic focus on the extended stay segment, coupled with disciplined capital allocation and a strong growth pipeline, positions it favorably to meet its net room growth outlook of 3.6%-4.6% for FY25, underpinning a positive long-term outlook for the company's stock.

Bear case

Wyndham Hotels & Resorts is projected to experience Adjusted EBITDA growth of only 5%-7%, which falls short of the previously anticipated 8.5% CAGR from 2024-2026, indicating potential operational inefficiencies. The company faces negative dynamics in RevPAR, with a 2.9% decline observed in March and an 8% decrease in China's market due to pricing pressures, reflecting weakening demand in key markets. Additionally, the ongoing macroeconomic challenges, including a slowdown in development opportunities and adverse impacts from natural disasters, further complicate the company’s growth prospects, leading to an overall negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.